Minimal influence of tocilizumab on IFN-γ synthesis by tuberculosis antigens

Modern Rheumatology

Volumn 20, Issue 2, 2010, Pages 130-133

  Ogata, Atsushi ^a   Mori, Masahide ^b   Hashimoto, Shoji ^c   Yano, Yukihiro ^b   Fujikawa, Takeya ^b   Kawai, Mari ^a   Kuwahara, Yusuke ^a   Hirano, Toru ^a   Arimitsu, Junsuke ^a   Hagihara, Keisuke ^a   Shima, Yoshihito ^a   Narazaki, Masashi ^a   Yokota, Souichirou ^b   Kishimoto, Tadamitsu ^d   Kawase, Ichiro ^a   Tanaka, Toshio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TONEYAMA NATIONAL HOSPITAL   (Japan)

^c OSAKA UNIVERSITY HOSPITAL   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Interferon gamma; Interleukin 6; Tocilizumab; Tuberculosis; Tumor necrosis factor

Indexed keywords

CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; IMMUNOSTIMULATION; PRIORITY JOURNAL; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; TUBERCULOSIS;

EID: 77954761056     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0243-4     Document Type: Article

References (11)

1. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148-55.
2. Jacobs M, Togbe D, Fremond C, Samarina A, Allie N, Botha T, et al. Tumor necrosis factor is critical to control tuberculosis infection. Microbes Infect. 2007;9:623-8. (Pubitemid 46628779)
3. Lalvani A. Diagnostic tuberculosis infection in the 21st century. Chest. 2007;131:1898-906.
4. Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, Baron G, Lemann M, Puechal X, Breban M, Berenbaum F, Delchier JC, Flipo RM, Dautzenberg B, Salmon D, Humbert M, Emilie D; RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther. 2006;8:R114.
5. Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumornecrosis- factor blockers: differential effects on mycobacterial immunity. J Infect Dis. 2006;194:486-92.
6. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-7.
7. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Alten R, et al;OPTION Investigators. Effect of interleukin-6 receptor inhibitionwith tocilizumab in patients with rheumatoid arthritis (OPTION study). A double-blind, placebocontrolled, randomised trial. Lancet. 2008;371:987-97.
8. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006;36:159-67.
9. Diehl S, Rincón M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol. 2002;39:531-6.
10. Salvana EM, Cooper GS, Salata RA. Mycobacterium other than tuberculosis (MOTT) infection: An emerging disease in infliximab- treated patients. J Infect. 2007;55:484-7.
11. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol. 2007;19:362-71.